Journal profile · ENGINEERING, BIOMEDICAL
Regenerative Engineering and Translational Medicine
ISSN 2364-4133 · eISSN 2364-4141 · Springer Nature · 4 issues per year
Regenerative Engineering and Translational Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.1 (journal website); hybrid open access; APC about USD 3,090; median 152 days to acceptance (91 articles, last 24 months); 150 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Regenerative Engineering and Translational Medicine is published by Springer Nature and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Electrospun Nanofibers in Biomedical Applications, Bone Tissue Engineering Materials and Tissue Engineering and Regenerative Medicine, together about 33.2% of its articles. Its main subfields are Biomedical Engineering. (generated from OpenAlex topic counts and CAS ranking data)
Regenerative Engineering and Translational Medicine is an international journal covering convergence of the disciplines of tissue engineering, advanced materials science, stem cell research, the physical sciences, and areas of developmental biology. This convergence brings exciting opportunities to translate bench-top research into bedside methods, allowing the possibility of moving beyond maintaining or repairing tissues to regenerating them. The journal encourages both top-down engineering approaches and bottom-up strategies integrating materials science with stem cell research and developmental biology. Convergence papers on instructive biomaterials, stimuli-responsive biomaterials, micro- and nano-patterning for regenerative engineering, elastomeric biomaterials, hydrogels for tissue engineering, and rapid prototyping and bioprinting approaches are particularly welcome. The journal provides a premier, single-blind peer-reviewed forum for the publication of original papers, authoritative reviews, rapid communications, news and views, and opinion papers addressing the most important issues and efforts toward successfully regenerating complex human tissues and organs. All research articles feature a lay abstract highlighting the relevance and future impact for patients, government and other health officials, and members of the general public. Bridging the gap between the lab and the clinic, the journal also serves as a dedicated platform for showcasing translational research that brings basic scientific research and discoveries into clinical methods and therapies, contributing to the improvement of human health care. Topics covered in Regenerative Engineering and Translational Medicine include: Advanced materials science for regenerative and biomedical applications Stem cells for tissue regeneration Drug delivery for tissue regeneration Nanomaterials and nanobiotechnology for tissue regeneration Studies combining tissue engineering/regeneration with developmental biology Convergence research in pre-clinical and clinical phases
From the journal's Aims & Scope
Research area (LetPub): ENGINEERING, BIOMEDICAL
Editor-in-chief Cato T. LaurencinPublisher website
Editorial board by country: 4 in mainland China (about 4%); most named United States 77, Mainland China 4, India 4, Canada 4, Israel 2 (98 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science13.3%
- Bone Tissue Engineering MaterialsEngineering10.3%
- Tissue Engineering and Regenerative MedicineMedicine9.6%
- 3D Printing in Biomedical ResearchEngineering8.7%
- Mesenchymal stem cell researchMedicine8.6%
- Wound Healing and TreatmentsMedicine6.4%
- Osteoarthritis Treatment and MechanismsMedicine4.3%
- Graphene and Nanomaterials ApplicationsEngineering3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Engineering, Biomedical | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Engineering, Biomedical | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 3.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.9Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.53LetPub ·
- SNIP 2026-06
- 0.61LetPub ·
- h-index
- 36OpenAlex ·
- i10-index
- 157OpenAlex ·
- 2-year mean citedness
- 2.53OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 13.72%LetPub ·
Volume
- Articles per year
- 146LetPub ·
- Articles per year (publisher)
- 2,024Publisher website ·
- Downloads per year (publisher) 2025
- 136,700Publisher website ·
Articles by year OpenAlex count · 625 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 103 | 11 | 33 |
| 2025 | 150 | 37 | 365 |
| 2024 | 44 | 4 | 354 |
| 2023 | 39 | 11 | 240 |
| 2022 | 50 | 10 | 480 |
| 2021 | 46 | 15 | 696 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
152 daysMedian, submission to acceptance · P25–P75 103 days – 213 days
- Acceptance to online
- median 24 days (91 articles)
- Submission to online
- median 182 days
- Sample
- 91 articles with submission and acceptance dates (273 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 9 daysPublisher website ·
- Peer review
- Double anonymous peer review, Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,090 / EUR 2,490 / GBP 2,190 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Graphical abstract
- Required
Article types accepted7, with length limits
- editorialThe General Guidance to manuscript format and content is presented below. The Rapid Communications and the News and Views articles deviate in format and content…main text ≤ 1,300 words · figures and tables ≤ 5
- news and views articlesNews and Views Articles: News and Views Articles are usually solicited by the Editors, although unsolicited material will also be considered.Length not stated
- original researchOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…Length not stated
- rapid communicationOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…Length not stated
- rapid communicationsRapid Communications: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in the format of an ar…Length not stated
- review articleOriginal Research: Regenerative Engineering and Translational Medicine welcomes scientific reports of original research and innovation in convergence of the dis…Length not stated
- review articlesReview Articles: Review Articles are actively encouraged and should be submitted via the journal’s electronic submission system.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Competing Interests
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclo…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Retrospective ethics approval Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Regenerative Engineering and Translational Medicine, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
Suggesting / excluding reviewers Model summary
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 4 issues per year
- ISSN
- 2364-4133
- Electronic ISSN
- 2364-4141
- Society / sponsor
- Regenerative Engineering Society
- Latest issue on the website
- Volume 12, Issue 2 (June 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Regenerative Engineering and Translational Medicine
What CAS zone is Regenerative Engineering and Translational Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Regenerative Engineering and Translational Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Engineering, Biomedical. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Regenerative Engineering and Translational Medicine?
The journal's website gives an impact factor of 3.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.9, h-index 36.
How long does peer review take at Regenerative Engineering and Translational Medicine?
Based on the dates recorded on 91 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 152 days (interquartile range 103–213 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Regenerative Engineering and Translational Medicine?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Regenerative Engineering and Translational Medicine based?
Of the 98 board members whose country the journal's board page names, 4 (about 4%) are in mainland China; the countries named most often are United States (77), Mainland China (4) and India (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Regenerative Engineering and Translational Medicine?
According to LetPub and DOAJ records, Regenerative Engineering and Translational Medicine is indexed in ESCI and Scopus. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Regenerative Engineering and Translational Medicine open access, and what is the APC?
Regenerative Engineering and Translational Medicine is a hybrid journal. For open-access publication: APC about USD 3,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .